Loading viewer...
investor_presentation
Format: PDF investor_presentation
Investor Conference Call: Fourth Quarter and Full Year 2019 Financial Results and Business Update February 13, 2020
Investor Conference Call:
Fourth Quarter and Full Year 2019 Financial Results
February 13, 2020 2 ©2020 Karyopharm Therapeutics Inc. •Michael G. Kauffman, MD, PhD, Chief Executive Officer
•Mike Mason, MBA, Chief Financial OfficerOn Today’s Call
•Perry Monaco, Senior Vice President, Sales
•Christopher Primiano, JD, MBA , Chief Business Officer & General Counsel
•Jatin Shah, MD, Executive Vice President, Chief Medical Officer
•Ian Karp, MBA, Vice President, Investor and Public RelationsJoining for
Q&A Session 3 ©2020 Karyopharm Therapeutics Inc. This presentation contains forward -looking statements within themeaning ofthe“safeharbor” provisions ofThe Private Securities Litigation Reform Actof1995 .Such forward -
looking statements include those regarding Karyopharm’s expectations relating toXPOVIO®forthetreatment ofpatients with heavily pretreated multiple myeloma, thetherapeutic
potential ofandpotential clinical development plans andcommercialization forKaryopharm’s drug candidates, including thetiming ofinitiation ofcertain trials, ofthereporting of
data from such trials, ofthesubmissions toregulatory authorities andofpotential commercial launches ;thepotential availability ofaccelerated approval pathways ;thepotential size
ofthemarkets formultiple myeloma drugs andmultiple myeloma drugs fortreatment ofpatients withrelapsed multiple myeloma ;thepotential sizeofthemarkets fordiffuse large B-
celllymphoma (DLBCL) drugs andDLBCL drugs fortreatment ofpatients withrelapsed and/orrefractory DLBCL ;andKaryopharm’s strategic andfinancial plans andexpectations
aswellasfinancial projections forKaryopharm .Such statements aresubject tonumerous important factors, risks anduncertainties thatmay cause actual events orresults todiffer
materially fromKaryopharm’s current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO, thatregulators willagree
thatselinexor qualifies forconditional approval intheE.U.asaresult ofthedata from theSTORM study inpatients with penta -refractory myeloma oraccelerated approval inthe
U.S.based ontheSADAL study inpatients with relapsed/refractory DLBCL orthat any ofKaryopharm’s drug candidates, including selinexor and eltanexor (KPT -8602 ),
Karyopharm’s second generation SINE compound, orKPT-9274 ,Karyopharm’s first-in-class oraldual inhibitor ofPAK4andNAMPT, oranyother drug candidate Karyopharm is
developing, willsuccessfully complete necessary preclinical andclinical development phases orthatdevelopment ofanyofKaryopharm’s drug candidates willcontinue .Further,
there canbenoguarantee thatanypositive developments inthedevelopment orcommercialization ofKaryopharm’s drug candidate portfolio willresult instock price appreciation .
Inaddition, even ifKaryopharm receives marketing approval forselinexor inadditional indications orforanyother drug candidate, there canbenoassurance thatKaryopharm will
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
35 Pages
ICAPE Group